top of page
Browse by category
Search
REDEFINE 1 trial: CagriSema demonstrates superior weight loss in adults with obesity or overweight
Headline results from Novo Nordisk’s REDEFINE 1 has shown that the trial achieved its primary endpoint by demonstrating a statistically...
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...
Browse by tag
bottom of page